Shandong Boyuan Pharmaceutical & Chemical Co., Ltd. (SHE:301617)
China · Delayed Price · Currency is CNY 53.90
0.00 (0.00%)
At close: Oct 8, 2026
SHE:301617 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,491 | 1,464 | 1,326 | 1,021 | 796.66 | 523.69 |
Other Revenue | 1.34 | 0.59 | 2.01 | 3.68 | 1.82 | 0.68 |
| 1,492 | 1,465 | 1,328 | 1,025 | 798.47 | 524.37 | |
Revenue Growth | 8.20% | 10.30% | 29.53% | 28.39% | 52.27% | 38.20% |
Cost of Revenue | 1,203 | 1,169 | 999.33 | 739.4 | 520.8 | 347.04 |
Gross Profit | 289.54 | 295.56 | 328.55 | 285.75 | 277.67 | 177.33 |
Selling, General & Admin | 50.39 | 46.29 | 42.84 | 37.47 | 36.85 | 29.92 |
Research & Development | 46.34 | 52.68 | 41.34 | 35.67 | 30.48 | 21.42 |
Other Operating Expenses | -2.2 | -1.62 | 1.04 | -0.78 | 3.23 | 1.21 |
Operating Expenses | 97.58 | 100.15 | 86.78 | 76.12 | 70.34 | 52.44 |
Operating Income | 191.96 | 195.41 | 241.77 | 209.64 | 207.33 | 124.89 |
Interest Expense | -0.04 | -0.06 | -0.28 | -0 | -0.46 | -1.97 |
Interest & Investment Income | 9.59 | 6.25 | 3.24 | 1.14 | 0.51 | 0.13 |
Currency Exchange Gain (Loss) | -0.11 | -1.4 | -1.18 | 0.11 | 0.35 | -0.02 |
Other Non Operating Income (Expenses) | -0.82 | -0.28 | -0.07 | -0.15 | -0.52 | -0.18 |
EBT Excluding Unusual Items | 200.58 | 199.92 | 243.48 | 210.74 | 207.21 | 122.85 |
Gain (Loss) on Sale of Investments | - | - | -4.58 | -2.31 | -1.85 | -1.4 |
Gain (Loss) on Sale of Assets | 0.04 | 0.1 | -0.03 | - | 0.34 | - |
Asset Writedown | -0.85 | -3.47 | - | -0.55 | -4.39 | -3.77 |
Other Unusual Items | -2.79 | -0.58 | 5.47 | - | - | - |
Pretax Income | 196.99 | 195.97 | 244.36 | 207.88 | 201.31 | 117.69 |
Income Tax Expense | 26.15 | 23.68 | 31.52 | 25.78 | 24.99 | 14.4 |
Net Income | 170.84 | 172.29 | 212.84 | 182.1 | 176.32 | 103.29 |
Net Income to Common | 170.84 | 172.29 | 212.84 | 182.1 | 176.32 | 103.29 |
Net Income Growth | -9.92% | -19.05% | 16.88% | 3.28% | 70.70% | 61.30% |
Shares Outstanding (Basic) | 174 | 174 | 100 | 130 | 130 | 125 |
Shares Outstanding (Diluted) | 174 | 174 | 100 | 130 | 130 | 125 |
Shares Change | 42.37% | 73.20% | -23.12% | 0.08% | 4.17% | 0.84% |
EPS (Basic) | 0.98 | 0.99 | 2.12 | 1.40 | 1.35 | 0.83 |
EPS (Diluted) | 0.98 | 0.99 | 2.12 | 1.40 | 1.35 | 0.83 |
EPS Growth | -36.73% | -53.26% | 52.03% | 3.20% | 63.88% | 60.41% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -148.34 | -88.07 | 106.31 | 79.26 | 53.9 | 11.58 |
Free Cash Flow Per Share | -0.85 | -0.51 | 1.06 | 0.61 | 0.41 | 0.09 |
Dividend Per Share | 0.254 | 0.308 | 0.355 | - | - | - |
Dividend Growth | -50.10% | -13.32% | - | - | - | - |
Gross Margin | 19.40% | 20.18% | 24.74% | 27.87% | 34.78% | 33.82% |
Operating Margin | 12.86% | 13.34% | 18.21% | 20.45% | 25.97% | 23.82% |
Profit Margin | 11.45% | 11.76% | 16.03% | 17.76% | 22.08% | 19.70% |
Free Cash Flow Margin | -9.94% | -6.01% | 8.01% | 7.73% | 6.75% | 2.21% |
EBITDA | 236.2 | 228.97 | 270.79 | 233.82 | 228.5 | 144.2 |
EBITDA Margin | 15.83% | 15.63% | 20.39% | 22.81% | 28.62% | 27.50% |
D&A For EBITDA | 44.23 | 33.56 | 29.02 | 24.18 | 21.17 | 19.31 |
EBIT | 191.96 | 195.41 | 241.77 | 209.64 | 207.33 | 124.89 |
EBIT Margin | 12.86% | 13.34% | 18.21% | 20.45% | 25.97% | 23.82% |
Effective Tax Rate | 13.27% | 12.08% | 12.90% | 12.40% | 12.41% | 12.23% |
Revenue as Reported | 1,492 | 1,465 | 1,328 | - | - | - |
Advertising Expenses | - | 1.44 | 1.01 | 1 | 0.46 | 0.21 |